Prime Medicine, Inc.
NASDAQ:PRMEBiotechnology
-$0.04 today
- Market cap
- $698.58M
- Beta
- 2.31
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.12
Volume 3.99M
Average 2.47M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Prime Medicine, Inc.
NASDAQ:PRME
Intrinsic Alpha fair value
Locked
Current Price
$3.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | +87.0% (5yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Forward estimates point to Revenue at +87.0% (5yr), giving you a quick read on expected growth from here.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
CRISPR Therapeutics AG NASDAQ:CRSP | $4.10B | $42.24 | Not rated | -9.2 | -21.02% |
Beam Therapeutics Inc. NASDAQ:BEAM | $2.36B | $22.83 | Not rated | -52.3 | +1.65% |
Intellia Therapeutics, Inc. NASDAQ:NTLA | $1.36B | $9.70 | Not rated | -4.6 | +18.41% |
Design Therapeutics, Inc. NASDAQ:DSGN | $670.46M | $10.47 | Not rated | -10.7 | +18.42% |
Editas Medicine, Inc. NASDAQ:EDIT | $334.92M | $2.17 | Not rated | -2.4 | -30.77% |
Scribe Therapeutics Inc. NASDAQ:SCTX | $264.74M | $16.36 | Not rated | — | — |
Caribou Biosciences, Inc. NASDAQ:CRBU | $39.10M | $0.36 | Not rated | -1.1 | -72.03% |
Continue the stock analysis
Jump to another research area for this company.